HIV-1–specific CD4+ T lymphocyte turnover and activation increase upon viral rebound

HIV-specific CD4+ T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form part of therapeutic manipulations, there is grave concern that the resumption of viral replication might destroy, perhaps irreversibly, thes...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 115; no. 2; pp. 443 - 450
Main Authors Scriba, Thomas J., Zhang, Hua-Tang, Brown, Helen L., Oxenius, Annette, Tamm, Norbert, Fidler, Sarah, Fox, Julie, Weber, Jonathan N., Klenerman, Paul, Day, Cheryl L., Lucas, Michaela, Phillips, Rodney E.
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 01.02.2005
Subjects
Online AccessGet full text
ISSN0021-9738
DOI10.1172/JCI200523084

Cover

Abstract HIV-specific CD4+ T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form part of therapeutic manipulations, there is grave concern that the resumption of viral replication might destroy, perhaps irreversibly, these T helper populations. High viremia blocks the proliferation capacity of HIV-specific helper cells. However, cytokine production assays imply that some antigen-specific effector function is retained. Despite this careful work, it remains unclear whether the return of HIV-1 replication physically destroys HIV-1-specific T helper cells in the peripheral blood. Difficulties in producing stable peptide-MHC class II complexes and the very low frequencies of antigen-specific CD4+ T cells have delayed the application of this powerful technique. Here we employ HLA class II tetramers and validate a sensitive, quantitative cell-enrichment technique to detect HIV-1 T helper cells. We studied patients with early-stage HIV infection who were given a short, fixed course of ART as part of a clinical study. We did not find significant deletion of these cells from the peripheral circulation when ART was stopped and unfettered HIV replication returned. The turnover of these virus-specific cells increased and they adopted an effector phenotype when viremia returned.
AbstractList HIV-specific CD4 + T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form part of therapeutic manipulations, there is grave concern that the resumption of viral replication might destroy, perhaps irreversibly, these T helper populations. High viremia blocks the proliferation capacity of HIV-specific helper cells. However, cytokine production assays imply that some antigen-specific effector function is retained. Despite this careful work, it remains unclear whether the return of HIV-1 replication physically destroys HIV-1–specific T helper cells in the peripheral blood. Difficulties in producing stable peptide-MHC class II complexes and the very low frequencies of antigen-specific CD4 + T cells have delayed the application of this powerful technique. Here we employ HLA class II tetramers and validate a sensitive, quantitative cell-enrichment technique to detect HIV-1 T helper cells. We studied patients with early-stage HIV infection who were given a short, fixed course of ART as part of a clinical study. We did not find significant deletion of these cells from the peripheral circulation when ART was stopped and unfettered HIV replication returned. The turnover of these virus-specific cells increased and they adopted an effector phenotype when viremia returned.
HIV-specific CD4+ T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form part of therapeutic manipulations, there is grave concern that the resumption of viral replication might destroy, perhaps irreversibly, these T helper populations. High viremia blocks the proliferation capacity of HIV-specific helper cells. However, cytokine production assays imply that some antigen-specific effector function is retained. Despite this careful work, it remains unclear whether the return of HIV-1 replication physically destroys HIV-1-specific T helper cells in the peripheral blood. Difficulties in producing stable peptide-MHC class II complexes and the very low frequencies of antigen-specific CD4+ T cells have delayed the application of this powerful technique. Here we employ HLA class II tetramers and validate a sensitive, quantitative cell-enrichment technique to detect HIV-1 T helper cells. We studied patients with early-stage HIV infection who were given a short, fixed course of ART as part of a clinical study. We did not find significant deletion of these cells from the peripheral circulation when ART was stopped and unfettered HIV replication returned. The turnover of these virus-specific cells increased and they adopted an effector phenotype when viremia returned.
Author Klenerman, Paul
Zhang, Hua-Tang
Oxenius, Annette
Day, Cheryl L.
Tamm, Norbert
Brown, Helen L.
Phillips, Rodney E.
Scriba, Thomas J.
Fidler, Sarah
Weber, Jonathan N.
Fox, Julie
Lucas, Michaela
AuthorAffiliation 1 Peter Medawar Building for Pathogen Research and Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. 2 Institute for Microbiology, Eidgenössische Technische Hochschule Zurich, Zurich, Switzerland. 3 Department of Medicine, Imperial College, St. Mary’s Hospital, London, United Kingdom
AuthorAffiliation_xml – name: 1 Peter Medawar Building for Pathogen Research and Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. 2 Institute for Microbiology, Eidgenössische Technische Hochschule Zurich, Zurich, Switzerland. 3 Department of Medicine, Imperial College, St. Mary’s Hospital, London, United Kingdom
Author_xml – sequence: 1
  givenname: Thomas J.
  surname: Scriba
  fullname: Scriba, Thomas J.
– sequence: 2
  givenname: Hua-Tang
  surname: Zhang
  fullname: Zhang, Hua-Tang
– sequence: 3
  givenname: Helen L.
  surname: Brown
  fullname: Brown, Helen L.
– sequence: 4
  givenname: Annette
  surname: Oxenius
  fullname: Oxenius, Annette
– sequence: 5
  givenname: Norbert
  surname: Tamm
  fullname: Tamm, Norbert
– sequence: 6
  givenname: Sarah
  surname: Fidler
  fullname: Fidler, Sarah
– sequence: 7
  givenname: Julie
  surname: Fox
  fullname: Fox, Julie
– sequence: 8
  givenname: Jonathan N.
  surname: Weber
  fullname: Weber, Jonathan N.
– sequence: 9
  givenname: Paul
  surname: Klenerman
  fullname: Klenerman, Paul
– sequence: 10
  givenname: Cheryl L.
  surname: Day
  fullname: Day, Cheryl L.
– sequence: 11
  givenname: Michaela
  surname: Lucas
  fullname: Lucas, Michaela
– sequence: 12
  givenname: Rodney E.
  surname: Phillips
  fullname: Phillips, Rodney E.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15668739$$D View this record in MEDLINE/PubMed
BookMark eNptkMlOwzAQhn0oogvcOCPfIeB4SZwDBxSWFlXiUnqNHMemRqkdOYvUG-_AG_IkBMpSEKfRaL5_ZvSNwcA6qwA4CtFZGMb4_C6dYYQYJojTARghhMMgiQkfgnFdPyEUUsroPhiGLIp4TJIRWE5nyyB8fX6pKyWNNhKmV_QELmC5WVcrJzeNgk3rreuUh8IWUMjGdKIxzkJjpVeiVrCt-q4zXpTQq9y1tjgAe1qUtTr8rBPwcHO9SKfB_P52ll7OA0kYagJMRBEprZAmgrAExRprQqIkYYTFueBxLguqVaKlyDljOOdJjBRHUpMi4gqRCbjY7q3afK0KqWzTf5FV3qyF32ROmOz3xJpV9ui6jFEaIdbnj3fz38EvQT1wugWkd3Xtlf5BUPbuPNt13uP4Dy5N82Grv27K_0NvB3-H9g
CitedBy_id crossref_primary_10_4049_jimmunol_175_10_6948
crossref_primary_10_1002_eji_200635886
crossref_primary_10_1128_JVI_00056_12
crossref_primary_10_1007_s11904_006_0002_5
crossref_primary_10_1128_JVI_00485_08
crossref_primary_10_1084_jem_20121437
crossref_primary_10_1016_j_clim_2015_02_009
crossref_primary_10_1371_journal_ppat_0030144
crossref_primary_10_1097_01_aids_0000176224_56108_fb
crossref_primary_10_1097_01_COH_0000194103_28063_35
crossref_primary_10_1097_01_COH_0000194107_20439_91
crossref_primary_10_1002_eji_200737648
crossref_primary_10_1016_j_virol_2006_10_040
crossref_primary_10_1086_522966
crossref_primary_10_1371_journal_ppat_1005832
crossref_primary_10_4161_hv_18432
crossref_primary_10_1111_j_1365_2249_2006_03193_x
crossref_primary_10_1164_rccm_200907_1011OC
crossref_primary_10_1371_journal_pone_0000649
crossref_primary_10_1586_erv_10_66
crossref_primary_10_1128_JVI_00249_06
crossref_primary_10_4049_jimmunol_1000156
crossref_primary_10_1007_s11010_009_0293_0
crossref_primary_10_1038_sj_icb_7100015
crossref_primary_10_1042_CS20050157
crossref_primary_10_1371_journal_pone_0000300
crossref_primary_10_1002_hep_20669
crossref_primary_10_1038_ni1241
crossref_primary_10_1128_JVI_00070_06
crossref_primary_10_1172_JCI46023
crossref_primary_10_1097_QAI_0b013e3181aeccdc
crossref_primary_10_1371_journal_pone_0188250
crossref_primary_10_1002_cyto_a_20603
crossref_primary_10_1111_j_1365_2567_2007_02801_x
crossref_primary_10_1016_j_it_2005_07_005
crossref_primary_10_1089_vim_2019_0186
crossref_primary_10_1097_COH_0b013e328011aab1
crossref_primary_10_1002_eji_200940102
crossref_primary_10_4049_jimmunol_175_10_6334
crossref_primary_10_1097_QAD_0b013e328339fe0b
crossref_primary_10_1111_j_1365_2249_2008_03653_x
crossref_primary_10_4049_jimmunol_0803548
Cites_doi 10.1182/blood-2003-04-1203
10.1038/8400
10.1002/eji.200424898
10.1086/318545
10.1073/pnas.97.10.5393
10.1084/jem.194.9.1277
10.1073/pnas.97.7.3382
10.1128/JVI.75.24.11983-11991.2001
10.1038/35035103
10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V
10.1128/JVI.77.20.10900-10909.2003
10.1146/annurev.immunol.22.012703.104702
10.4049/jimmunol.159.4.1686
10.1073/pnas.190335897
10.1182/blood-2001-11-0080
10.1097/00002030-200210180-00010
10.1084/jem.187.8.1295
10.1086/342559
10.1089/088922299310485
10.1084/jem.191.9.1499
10.1172/JCI200318509
10.1128/JVI.76.12.5925-5936.2002
10.1073/pnas.251539598
10.1172/JCI8476
10.1111/j.1399-0039.1995.tb03127.x
10.1002/1521-4141(200112)31:12<3782::AID-IMMU3782>3.0.CO;2-#
10.1073/pnas.250472097
10.1182/blood-2003-09-3333
10.4049/jimmunol.172.5.3337
10.1084/jem.20041270
10.1086/315202
10.1086/315379
10.1073/pnas.202372199
10.1172/JCI8943
10.1073/pnas.96.26.15109
10.1038/44385
10.1038/417095a
10.1084/jem.20031598
10.4049/jimmunol.167.11.6663
10.1128/JVI.78.13.7284-7287.2004
10.1126/science.278.5342.1447
10.1038/4772
ContentType Journal Article
Copyright Copyright © 2005, American Society for Clinical Investigation 2005
Copyright_xml – notice: Copyright © 2005, American Society for Clinical Investigation 2005
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
5PM
DOI 10.1172/JCI200523084
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 450
ExternalDocumentID PMC544605
15668739
10_1172_JCI200523084
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.GJ
.XZ
08G
08P
29K
2WC
354
36B
53G
5GY
5RE
5RS
7RV
7X7
88E
8AO
8F7
8FE
8FH
8FI
8FJ
8R4
8R5
AAWTL
AAYOK
AAYXX
ABOCM
ABPMR
ABUWG
ACGFO
ACIHN
ACNCT
ACPRK
ADBBV
AEAQA
AENEX
AFCHL
AFFNX
AFKRA
AHMBA
AI.
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ASPBG
AVWKF
AZFZN
BAWUL
BBNVY
BCR
BCU
BEC
BENPR
BHPHI
BKEYQ
BLC
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D-I
DIK
DU5
E3Z
EBD
EBS
EJD
EMB
EMOBN
EX3
F5P
FRP
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
H~9
IAO
IEA
IHR
INH
IOF
IPO
KQ8
L7B
LK8
M1P
M5~
M7P
MVM
N4W
NAPCQ
OBH
OCB
ODZKP
OFXIZ
OGEVE
OHH
OK1
OVD
OVIDX
OVT
P2P
P6G
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
RPM
S0X
SJFOW
SV3
TEORI
TR2
TVE
UKHRP
VH1
VVN
W2D
WH7
WOQ
WOW
X7M
XSB
YFH
YHG
YKV
YOC
ZXP
ZY1
~H1
3O-
3V.
88A
AAKAS
ADZCM
CGR
CUY
CVF
ECM
EIF
FEDTE
HVGLF
IHW
INR
IOV
ISR
ITC
J5H
M0L
NPM
OHT
PKN
UHU
ZGI
5PM
PJZUB
PPXIY
PQGLB
ID FETCH-LOGICAL-c350t-23ad6efe0f3a35907f2f336995357ba87bcd4fe9fcab8552b8970e80cf3d68e03
ISSN 0021-9738
IngestDate Thu Aug 21 14:07:58 EDT 2025
Wed Feb 19 01:43:11 EST 2025
Thu Apr 24 23:01:38 EDT 2025
Tue Jul 01 03:47:52 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c350t-23ad6efe0f3a35907f2f336995357ba87bcd4fe9fcab8552b8970e80cf3d68e03
Notes Address correspondence to: Rodney E. Phillips, The Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, United Kingdom. Phone: 44-1865-281230; Fax: 44-1865-281890; E-mail: rodney.phillips@ndm.ox.ac.uk.
OpenAccessLink http://doi.org/10.1172/JCI200523084
PMID 15668739
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_544605
pubmed_primary_15668739
crossref_primary_10_1172_JCI200523084
crossref_citationtrail_10_1172_JCI200523084
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2005-02-01
PublicationDateYYYYMMDD 2005-02-01
PublicationDate_xml – month: 02
  year: 2005
  text: 2005-02-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of clinical investigation
PublicationTitleAlternate J Clin Invest
PublicationYear 2005
Publisher American Society for Clinical Investigation
Publisher_xml – name: American Society for Clinical Investigation
References B20
B23
B24
B25
B26
B27
B28
Chao (B21) 1997; 159
B30
B31
B10
B32
B11
B33
B12
Day (B22) 2003; 112
B34
B13
B35
Bunce (B42) 1995; 46
B14
B36
B15
B37
B38
B17
B39
B18
B19
Douek (B29) 2001; 167
B1
B2
Palmer (B16) 2004; 172
B3
B4
B5
B6
B7
B8
B9
B40
B41
11696593 - J Exp Med. 2001 Nov 5;194(9):1277-87
15381726 - J Exp Med. 2004 Sep 20;200(6):701-12
14676302 - J Exp Med. 2003 Dec 15;198(12):1909-22
10608758 - J Infect Dis. 2000 Jan;181(1):121-31
10382767 - Eur J Immunol. 1999 Jun;29(6):2037-45
10537110 - Nature. 1999 Oct 14;401(6754):708-12
10606619 - J Clin Invest. 1999 Dec;104(12):1669-70
10762561 - J Infect Dis. 2000 Apr;181(4):1249-63
11095734 - Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13778-83
9367954 - Science. 1997 Nov 21;278(5342):1447-50
10737796 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7
9257829 - J Immunol. 1997 Aug 15;159(4):1686-94
14978142 - J Immunol. 2004 Mar 1;172(5):3337-47
15032595 - Annu Rev Immunol. 2004;22:745-63
15162426 - Eur J Immunol. 2004 Jun;34(6):1570-7
12975468 - J Clin Invest. 2003 Sep;112(6):831-42
10229228 - Nat Med. 1999 May;5(5):518-25
11714838 - J Immunol. 2001 Dec 1;167(11):6663-8
10805798 - Proc Natl Acad Sci U S A. 2000 May 9;97(10):5393-8
11717444 - Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13878-83
11029005 - Nature. 2000 Sep 28;407(6803):523-6
12958069 - Blood. 2004 Feb 1;103(3):966-72
10611346 - Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14
11005833 - Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11433-8
11745399 - Eur J Immunol. 2001 Dec;31(12):3782-8
9883844 - Nat Med. 1999 Jan;5(1):83-9
10790425 - J Exp Med. 2000 May 1;191(9):1499-512
12149221 - Blood. 2002 Aug 15;100(4):1381-7
8838344 - Tissue Antigens. 1995 Nov;46(5):355-67
10606632 - J Clin Invest. 1999 Dec;104(12):R63-7
11711588 - J Virol. 2001 Dec;75(24):11983-91
11170994 - J Infect Dis. 2001 Feb 15;183(4):657-61
12370504 - AIDS. 2002 Oct 18;16(15):2049-54
9547340 - J Exp Med. 1998 Apr 20;187(8):1295-303
12021325 - J Virol. 2002 Jun;76(12):5925-36
15194806 - J Virol. 2004 Jul;78(13):7284-7
10445809 - AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):973-81
12195350 - J Infect Dis. 2002 Sep 1;186(5):634-43
14512540 - J Virol. 2003 Oct;77(20):10900-9
15117761 - Blood. 2004 Aug 15;104(4):942-7
11986671 - Nature. 2002 May 2;417(6884):95-8
12370434 - Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52
References_xml – ident: B18
  doi: 10.1182/blood-2003-04-1203
– ident: B12
  doi: 10.1038/8400
– ident: B25
  doi: 10.1002/eji.200424898
– ident: B7
  doi: 10.1086/318545
– ident: B30
  doi: 10.1073/pnas.97.10.5393
– ident: B28
  doi: 10.1084/jem.194.9.1277
– ident: B40
  doi: 10.1073/pnas.97.7.3382
– ident: B10
  doi: 10.1128/JVI.75.24.11983-11991.2001
– ident: B13
  doi: 10.1038/35035103
– ident: B20
  doi: 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V
– ident: B14
  doi: 10.1128/JVI.77.20.10900-10909.2003
– ident: B39
  doi: 10.1146/annurev.immunol.22.012703.104702
– volume: 159
  start-page: 1686
  year: 1997
  ident: B21
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.159.4.1686
– ident: B26
  doi: 10.1073/pnas.190335897
– ident: B19
  doi: 10.1182/blood-2001-11-0080
– ident: B27
  doi: 10.1097/00002030-200210180-00010
– ident: B32
  doi: 10.1084/jem.187.8.1295
– ident: B8
  doi: 10.1086/342559
– ident: B9
  doi: 10.1089/088922299310485
– ident: B24
  doi: 10.1084/jem.191.9.1499
– volume: 112
  start-page: 831
  year: 2003
  ident: B22
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI200318509
– ident: B11
  doi: 10.1128/JVI.76.12.5925-5936.2002
– ident: B2
  doi: 10.1073/pnas.251539598
– ident: B34
  doi: 10.1172/JCI8476
– volume: 46
  start-page: 355
  year: 1995
  ident: B42
  publication-title: Tissue Antigens.
  doi: 10.1111/j.1399-0039.1995.tb03127.x
– ident: B36
  doi: 10.1002/1521-4141(200112)31:12<3782::AID-IMMU3782>3.0.CO;2-#
– ident: B33
  doi: 10.1073/pnas.250472097
– ident: B37
  doi: 10.1182/blood-2003-09-3333
– volume: 172
  start-page: 3337
  year: 2004
  ident: B16
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.172.5.3337
– ident: B38
  doi: 10.1084/jem.20041270
– ident: B41
  doi: 10.1086/315202
– ident: B6
  doi: 10.1086/315379
– ident: B4
  doi: 10.1073/pnas.202372199
– ident: B35
  doi: 10.1172/JCI8943
– ident: B5
  doi: 10.1073/pnas.96.26.15109
– ident: B17
  doi: 10.1038/44385
– ident: B3
  doi: 10.1038/417095a
– ident: B15
  doi: 10.1084/jem.20031598
– volume: 167
  start-page: 6663
  year: 2001
  ident: B29
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.167.11.6663
– ident: B23
  doi: 10.1128/JVI.78.13.7284-7287.2004
– ident: B1
  doi: 10.1126/science.278.5342.1447
– ident: B31
  doi: 10.1038/4772
– reference: 10445809 - AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):973-81
– reference: 10737796 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7
– reference: 15194806 - J Virol. 2004 Jul;78(13):7284-7
– reference: 12195350 - J Infect Dis. 2002 Sep 1;186(5):634-43
– reference: 10229228 - Nat Med. 1999 May;5(5):518-25
– reference: 14978142 - J Immunol. 2004 Mar 1;172(5):3337-47
– reference: 9883844 - Nat Med. 1999 Jan;5(1):83-9
– reference: 9367954 - Science. 1997 Nov 21;278(5342):1447-50
– reference: 11170994 - J Infect Dis. 2001 Feb 15;183(4):657-61
– reference: 9547340 - J Exp Med. 1998 Apr 20;187(8):1295-303
– reference: 10606619 - J Clin Invest. 1999 Dec;104(12):1669-70
– reference: 10606632 - J Clin Invest. 1999 Dec;104(12):R63-7
– reference: 8838344 - Tissue Antigens. 1995 Nov;46(5):355-67
– reference: 15381726 - J Exp Med. 2004 Sep 20;200(6):701-12
– reference: 11095734 - Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13778-83
– reference: 10382767 - Eur J Immunol. 1999 Jun;29(6):2037-45
– reference: 11745399 - Eur J Immunol. 2001 Dec;31(12):3782-8
– reference: 12370504 - AIDS. 2002 Oct 18;16(15):2049-54
– reference: 10537110 - Nature. 1999 Oct 14;401(6754):708-12
– reference: 11717444 - Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13878-83
– reference: 10805798 - Proc Natl Acad Sci U S A. 2000 May 9;97(10):5393-8
– reference: 11714838 - J Immunol. 2001 Dec 1;167(11):6663-8
– reference: 10611346 - Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14
– reference: 15162426 - Eur J Immunol. 2004 Jun;34(6):1570-7
– reference: 10608758 - J Infect Dis. 2000 Jan;181(1):121-31
– reference: 15032595 - Annu Rev Immunol. 2004;22:745-63
– reference: 15117761 - Blood. 2004 Aug 15;104(4):942-7
– reference: 12958069 - Blood. 2004 Feb 1;103(3):966-72
– reference: 9257829 - J Immunol. 1997 Aug 15;159(4):1686-94
– reference: 11005833 - Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11433-8
– reference: 12149221 - Blood. 2002 Aug 15;100(4):1381-7
– reference: 10790425 - J Exp Med. 2000 May 1;191(9):1499-512
– reference: 11711588 - J Virol. 2001 Dec;75(24):11983-91
– reference: 11986671 - Nature. 2002 May 2;417(6884):95-8
– reference: 12975468 - J Clin Invest. 2003 Sep;112(6):831-42
– reference: 10762561 - J Infect Dis. 2000 Apr;181(4):1249-63
– reference: 11696593 - J Exp Med. 2001 Nov 5;194(9):1277-87
– reference: 12021325 - J Virol. 2002 Jun;76(12):5925-36
– reference: 12370434 - Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52
– reference: 14512540 - J Virol. 2003 Oct;77(20):10900-9
– reference: 11029005 - Nature. 2000 Sep 28;407(6803):523-6
– reference: 14676302 - J Exp Med. 2003 Dec 15;198(12):1909-22
SSID ssj0014454
Score 2.0006952
Snippet HIV-specific CD4+ T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form...
HIV-specific CD4 + T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can...
SourceID pubmedcentral
pubmed
crossref
SourceType Open Access Repository
Index Database
Enrichment Source
StartPage 443
SubjectTerms Antiretroviral Therapy, Highly Active
Cell Proliferation
Cells, Cultured
Histocompatibility Antigens Class II - immunology
Histocompatibility Antigens Class II - pharmacology
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - pathology
HIV-1 - physiology
Humans
Lymphocyte Activation - drug effects
Lymphocyte Activation - immunology
T-Lymphocytes, Helper-Inducer - immunology
T-Lymphocytes, Helper-Inducer - pathology
T-Lymphocytes, Helper-Inducer - virology
Viremia - immunology
Viremia - pathology
Virus Activation - physiology
Title HIV-1–specific CD4+ T lymphocyte turnover and activation increase upon viral rebound
URI https://www.ncbi.nlm.nih.gov/pubmed/15668739
https://pubmed.ncbi.nlm.nih.gov/PMC544605
Volume 115
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLbKkBAXxG_KL_nATlZGFttxfIQC6ioGB7Jpt8p2Ha3SlE2QSIwTR-78h_wlPMd2krIhDS5Rm9qpmvfV7_nle99D6AXVKhcQhyfgTWjCLIO_VGryRCgAixWVkdptFPc_5PMDtjjiR5PJjxFrqW30jvl2aV3J_1gVzoFdXZXsP1i2vyicgNdgXziCheF4JRvP9w6T3UhXoK5o0hF_yOwN285ek5KcnIOtTs15Ywl4ltqxNb04q4lNzci6dmHjF0vaM3jnGL9O6F-7ZkvjuHWoIOti176ecj3IdAzP8z_BSqTVQD8ii50L-el5q5JSBbc5Tgd0fpC872d8_Grrdet7JrsSokBMiokKHrnNw-Lr2CDCi7n0i68v5gwoy0ZLKfPyTcErMy9Pe3HBF05AdjHby3yC2_eb29TV_sPf9SzEbv8jsuV49jV0PXPYjXmf8DyKMR70vP1PiCUUIns5nr0R3PQRzSbbdhS-lLfRrWA7_MqD6A6a2PouurEfmBX30GGHpV_ff0YUYUARwSUeMIQjhjBgCA8YwhFD2GEIdxjCAUP30cG7t-VsnoSeG4mhPG2SjKpVbiubVlRRLlNRZRWluZSccqFVIbRZscrKyihdcJ7pQorUFqmp6CovbEofoK36tLaPELa7XFspIQrLYVtMITJ28o4rJSHmFEXOp4jEm7U0QZDe9UU5WV5mmCna7kefeSGWv4x76G_3MAp2LIWgcoryDUP0A5zC-uYn9fq4U1rnzNEGHl_xq5-gmwPun6Kt5nNrn0HI2ujnHZp-A6jVlCU
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIV-1%E2%80%93specific+CD4%2B+T+lymphocyte+turnover+and+activation+increase+upon+viral+rebound&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Scriba%2C+Thomas+J.&rft.au=Zhang%2C+Hua-Tang&rft.au=Brown%2C+Helen+L.&rft.au=Oxenius%2C+Annette&rft.date=2005-02-01&rft.issn=0021-9738&rft.volume=115&rft.issue=2&rft.spage=443&rft.epage=450&rft_id=info:doi/10.1172%2FJCI200523084&rft.externalDBID=n%2Fa&rft.externalDocID=10_1172_JCI200523084
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon